{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:13Z","timestamp":1792787293978,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1136\/ijgc-2023-004307","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T10:52:49Z","timestamp":1683111169000},"page":"1260-1269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["BRCA1\/2 testing rates in epithelial ovarian cancer: a focus on the untested patients"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-728X","authenticated-orcid":false,"given":"Lieke","family":"Lanjouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J.E.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"ter Elst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke P.V.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke H.","family":"van der Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naufil","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004307_bb0010","unstructured":"IKNL . Nederlandse kankerregistratie (NKR). n.d.Available: iknl.nl\/nkr-cijfers"},{"key":"10.1136\/ijgc-2023-004307_bb0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12687-017-0326-4","article-title":"Referral to cancer genetic counseling: do migrant status and patients\u2019 educational background matter?","volume":"8","author":"van der Giessen","year":"2017","journal-title":"J Community Genet"},{"key":"10.1136\/ijgc-2023-004307_bb0020","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004307_bb0025","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clon.2018.04.004","article-title":"Inadequate rates of BRCA testing with its negative consequences for women with epithelial ovarian cancer and their families: an overview of the literature","volume":"30","author":"Hoskins","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1136\/ijgc-2023-004307_bb0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2021.05.011","article-title":"Achieving universal genetic assessment for women with ovarian cancer: are we there yet? A systematic review and meta-analysis","volume":"162","author":"Lin","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004307_bb0035","author":"Commissie Richtlijnen Gynaecologische Oncologie (CRGO)","year":"2015","journal-title":"Richtlijn Erfelijk en familiar ovariumcarcinoom"},{"key":"10.1136\/ijgc-2023-004307_bb0040","author":"Commissie Richtlijnen Gynaecologische Oncologie (CRGO)","year":"2022","journal-title":"Richtlijn erfelijk en familiar ovariumcarcinoom"},{"key":"10.1136\/ijgc-2023-004307_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnci\/djz080","article-title":"Universal tumor DNA BRCA1\/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition","volume":"112","author":"Vos","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2023-004307_bb0050","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004307_bb0055","unstructured":"European Reference Networks . Genetic tumour risk syndromes (ERN GENTURIS). n.d.Available: https:\/\/www.genturis.eu\/l=eng\/Our-experts\/Our-healthcare-providers\/UMC-Groningen-NL.html"},{"key":"10.1136\/ijgc-2023-004307_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-2122-x","article-title":"The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient\u2019s perspective","volume":"17","author":"Sidorenkov","year":"2019","journal-title":"J Transl Med"},{"key":"10.1136\/ijgc-2023-004307_bb0065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.maturitas.2014.12.009","article-title":"Stopping ovarian cancer screening in BRCA1\/2 mutation carriers: effects on risk management decisions and outcome of risk-reducing salpingo-oophorectomy specimens","volume":"80","author":"van Driel","year":"2015","journal-title":"Maturitas"},{"key":"10.1136\/ijgc-2023-004307_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110435","article-title":"Next-generation service delivery: a scoping review of patient outcomes associated with alternative models of genetic counseling and genetic testing for hereditary cancer","volume":"10","author":"McCuaig","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004307_bb0075","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004307_bb0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2021.10.072","article-title":"Probability of detecting germline BRCA1\/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis","volume":"164","author":"Witjes","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004307_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0511-7","article-title":"Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","volume":"12","author":"Kim","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004307_bb0090","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004307_bb0095","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401658X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401658X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:18Z","timestamp":1753234158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2401658X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1048891X2401658X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004307","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA1\/2 testing rates in epithelial ovarian cancer: a focus on the untested patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}